Brief: First Wave BioPharma Announces Initiation Of Phase 2 Trial Of Enhanced Adrulipase Formulation

GridAI Technologies

31/01/2023 14:27

Jan 31 (Reuters) - First Wave BioPharma Inc  FWBI.O :
    * FIRST WAVE BIOPHARMA ANNOUNCES INITIATION OF PHASE 2 TRIAL
INVESTIGATING ENHANCED ADRULIPASE FORMULATION IN EXOCRINE
PANCREATIC INSUFFICIENCY IN PATIENTS WITH CYSTIC FIBROSIS
    * FIRST WAVE BIOPHARMA INC - EXPECTS TO INITIATE PATIENT
SCREENING
IN EARLY FEBRUARY 2023, WITH TOPLINE DATA ANTICIPATED BY
MID-2023
    * FIRST WAVE BIOPHARMA INC - THREE CLINICAL TRIAL SITES IN
U.S.
WILL BE PARTICIPATING IN TRIAL

Source text for Eikon:  ID:nGNX93wJjc 
Further company coverage:  FWBI.O 
 ((Reuters.Briefs@thomsonreuters.com;))